Organization
TESARO, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
TESARO, Inc.
... If you want a Stock Review on OPHT, PTCT, TRVN, or TSRO then come over tohttp://dailystocktracker.com/register/and sign up for your free customized report. Today's ...
... included revenue related to two milestones earned from the company's partnership with TESARO. The three and nine months ended September 30, 2016 included revenue of ...
... of cancer, today announced the signing of a collaborative agreement with TESARO, Inc. ('TESARO') to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab ...
... AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-0), ...
... - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and TESARO, Inc. ('TESARO') today announced a three-year integrated drug discovery collaboration to discover and ...
... MIAMI - OPKO Health, Inc. (NASDAQ: OPK) announces that its licensee, TESARO, Inc. (Nasdaq: TSRO), received U.S. Food and Drug Administration (FDA) approval for VARUBI ...
... polysorbate 80. 'The approval of VARUBI IV represents a significant milestone for TESARO. The majority of NK-1 receptor antagonist doses are administered intravenously in the ...
... of cancer, today announced the signing of a collaborative agreement with TESARO, Inc. ("TESARO") to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab ...
... (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces that its licensee, TESARO, Inc. (Nasdaq:TSRO), received U.S. Food and Drug Administration (FDA) approval for VARUBI® (rolapitant) ...
... content of this announcement. ------------------------------------------------------------ * DISCOVERY AND DEVELOPMENT OF INHIBITORS AGAINST TESARO'S IMMUNO-ONCOLOGY TARGET UTILISING EVOTEC'S COMPREHENSIVE DISCOVERY AND DEVELOPMENT PLATFORM Hamburg, Germany, 26 ...
... planned for November WALTHAM, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and ...
... WALTHAM, Mass., Oct. 24, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2017 financial results on Tuesday, November 7, ...
... (FWC), the official foundation of the Society of Gynecologic Oncology, and TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the continuation of their partnership ...
... WALTHAM, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming ...
... If you want a Stock Review on TSRO, TRVN, OMER, or RDUS then come over tohttp://dailystocktracker.com/register/and sign up for your ...
... support, include AbbVie, Astex Pharmaceuticals, Iovance Biotherapeutics, Mirati Therapeutics, Prometheus Laboratories, and TESARO. SU2C Catalyst is overseen by an Executive Committee chaired by Sharp and ...
... processes more efficiently and get medicines to patients much faster." Biopharmaceutical company TESARO implemented Vault Development Cloud applications Vault eTMF , Vault QMS , and ...
... WALTHAM - TESARO Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today the availability of ...
... WALTHAM, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, announced today the availability of a ...
... ZUG, Switzerland - TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, today announced that the European Medicines ...
... ZUG, Switzerland, Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency's ...
... MADRID, Spain, Sept. 11, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today provided a summary of ZEJULA and ...
... thought you had achieved a benefit from platinum chemotherapy—that is extraordinary.” RELATED: Tesaro undercut PARP rivals with $118K price tag on Zejula—or did it? Based ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤